araag2/HINT huggingface dataset:
Clinical trial NCT01004432 (phase 3, status: completed)
Conditions: arthritis, arthritis, rheumatoid, autoimmune diseases
ICD codes: A01.04, A02.23, A39.83, A39.84, A54.42, B06.82, B26.85, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, E06.3, K75.4, E31.0, D59.10, D59.11, D59.12, D59.19
Drugs: golimumab 50 mg sc, golimumab 2 mg/kg iv, methotrexate (mtx), placebo sc, placebo iv
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Have inadequate RA disease control prior to the first administration of study agent
             despite treatment with etanercept (Enbrel) + methotrexate or adalimumab (Humira) +
             methotrexate (MTX)

          -  Must have received a stable dose of MTX greater than or equal to (>=) 7.5 milligram
             (mg) per week to less than or equal to (<=) 25 mg per week for at least 4 consecutive
             weeks prior to the first screening visit and must plan to maintain that dose
             throughout the study

          -  Participants must have received etanercept or adalimumab in combination with MTX for a
             minimum of 3 months prior to the first visit

          -  Negative tuberculosis (TB) test

          -  Are capable of providing informed consent, which must be obtained prior to any
             study-related procedures

        Exclusion Criteria:

          -  Have a history of latent or active granulomatous infection, including TB,
             histoplasmosis, or coccidioidomycosis, or are frequently in contact with individuals
             who carry active TB infection

          -  Have inflammatory diseases other than RA, including but not limited to psoriatic
             arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary Sjogren's or
             Lyme disease

          -  Have demonstrated a discernible improvement in disease activity between screening and
             prior to the first golimumab injection at Week 0

          -  Have any known malignancy or have a history of malignancy within the previous 5 years
             (with the exception of a nonmelanoma skin cancer that has been treated with no
             evidence of recurrence)

          -  Have a history of lymphoproliferative disease, including lymphoma, or signs and
             symptoms suggestive of possible lymphoproliferative disease such as lymphadenopathy of
             unusual size or location
Clinical trial NCT00432614 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: sr58611a, escitalopram, placebo
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Inpatients or outpatients with Major Depressive Disorder characterized by a recurrent
             Major Depressive Episode with Montgomery and Asberg Depression Rating Scale (MADRS)
             total score => 30

        Exclusion Criteria:

          -  Patient is at immediate risk for suicidal behavior

          -  Patient with psychotic features, catatonic features, seasonal pattern or postpartum
             onset

          -  Patients with a current depressive episode secondary to a general medical disorder

          -  Patients with a lifetime history or presence of bipolar disorder, psychotic disorder,
             panic disorder and antisocial personality disorder

          -  Patients with severe or unstable concomitant medical conditions

          -  Pregnant, breastfeeding, or likely to become pregnant during the study

          -  Treated with escitalopram within 6 months before the study, or who have had an adverse
             reaction to escitalopram

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
Clinical trial NCT00423800 (phase 3, status: terminated)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: combination of pegylated interferon alfa-2b (peg) and ribavirin (rbv)
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Reason stopped: 
    the study was terminated due to difficulty in recruiting participants.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Must demonstrate willingness to participate in the study.

          -  Diagnosed with chronic HCV.

          -  Between 18 and 65 years of age of either gender and of any race.

          -  a. HCV positive, >600,000 IU/mL at baseline AND b. Genotype 1.

          -  Suitable for treatment with Pegetron® per the Canadian product monograph.

          -  Investigator has already decided to treat with PEGETRON REDIPEN®

        1.5mcg/kg/week of peginterferon alpha-2b plus 800-1200 mg /day of ribavirin.

          -  HCV-RNA negative at treatment week 4.

          -  Meet certain minimum laboratory values at the week 4 screening visit.

          -  Women of childbearing potential and male partners must agree to use a medically
             accepted method of contraception prior to screening, while receiving
             protocol-specified medication, and for 6 months after stopping the medication.
             Acceptable methods of contraception include condoms (male or female) with or without a
             spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed
             IUD, oral or injectable hormonal contraceptive, and surgical sterilization (e.g.
             hysterectomy or tubal ligation).

        Exclusion Criteria:

          -  Had previous interferon-based therapy for Chronic Hepatitis C.

          -  Active Hepatitis B virus (HBV) infection.

          -  Human Immunodeficiency Virus (HIV) antibody positive.

          -  Cirrhotic (Stage 4 on Metavir system).

          -  Uncontrolled history or current severe depression or psychoses.

          -  Uncontrolled epilepsy.

          -  Use of illicit drugs.

          -  History of non-compliance to medical regimens.

          -  Liver disease other than from chronic hepatitis C.

          -  Participating in any other clinical study.

          -  Used any investigational drugs within 30 days of screening.

          -  Participants weighing < 40 kg or > 125 kg.

          -  Pregnant women or women who plan to become pregnant or sexual partners of women who
             want to become pregnant.
Clinical trial NCT00666328 (phase 3, status: completed)
Conditions: hypertension, hemorrhage
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, K94.01, K94.11, K94.21, K94.31, N99.510, H11.33, H35.63
Drugs: clevidipine
SMILES: CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  CT evidence of intracerebral hemorrhage (diagnosis and treatment within 12 hours of
             symptom onset)

          -  Age 18 years or older

          -  Baseline systolic blood pressure (immediately prior to initiation of clevidipine) >160
             mmHg measured using an arterial line. ICP-monitored patients enrolled in the sub-study
             were enrolled if SBP at the time of enrollment was ≤160 mmHg

          -  Required antihypertensive therapy to achieve systolic blood pressure ≤160 mmHg

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Decision for early surgical evacuation prior to 30 minutes of clevidipine

          -  Receipt of an oral antihypertensive within 2 hours prior to initiation of clevidipine

          -  Treatment with a continuous infusion of an IV antihypertension agent prior to
             initiation of clevidipine. Bolus treatment with urapidil (Germany only), labetalol or
             hydralazine was permitted. ICP-monitored patients enrolled in the sub-study could be
             enrolled with a continuous infusion of an IV antihypertensive agent prior to the
             initiation of clevidipine.

          -  Intracerebral hematoma considered to be related to trauma by the neurologist or
             neurosurgeon

          -  Aneurysmal sub-arachnoid hemorrhage

          -  Glasgow coma score of <5 and fixed dilated pupils

          -  Expectation that the patient would not tolerate or require intravenous
             antihypertensive therapy for a minimum of 30 minutes

          -  Known or suspected aortic dissection

          -  Acute myocardial infarction on presentation

          -  Positive pregnancy test or known pregnancy

          -  Intolerance or allergy to calcium channel blockers

          -  Allergy to soybean oil or egg lecithin

          -  Known liver failure, cirrhosis or pancreatitis

          -  Prior directives against advanced life support

          -  Participation in other clinical research studies involving the evaluation of other
             investigational drugs or devices within 30 days of enrollment
Clinical trial NCT00191477 (phase 3, status: terminated)
Conditions: bladder neoplasms
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: gemcitabine, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was stopped early for futility reasons.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical evidence of superficial transitional cell carcinoma of the bladder

          -  Males or females at least 18 years of age

          -  Karnofsky Performance Status greater than or equal to 70%

          -  Patient compliance and geographic proximity that allow adequate follow-up

          -  Female patients with reproductive potential must use a reliable contraceptive method
             if appropriate (for example, intrauterine device [IUD], birth control pills, or
             barrier device) during the study. Female patients with reproductive potential must
             have a negative serum pregnancy test within 7 days of study enrollment.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Clinical evidence of muscle-invasive or locally advanced bladder cancer

          -  Clinical evidence of upper urinary tract tumor

          -  Distant metastases

          -  Other malignancies within the last 2 years, except non-melanotic skin tumors,
             carcinoma in situ of the cervix or organ-confined prostate cancer after curative
             therapy

          -  Severe concomitant psychiatric disease

          -  Febrile, active infection

          -  Other serious concomitant disorders that would compromise the safety of the patient or
             his/her ability to complete the study according to the protocol, at the discretion of
             the investigator (for example, unstable angina pectoris, uncontrolled diabetes
             mellitus)
Clinical trial NCT00430508 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: olmesartan medoxomil (om)/hydrochlorothiazide (hctz) tablets and placebo, olmesartan medoxomil (om)/hydrochlorothiazide (hctz) tablets, olmesartan medoxomil/hydrochlorothiazide tablets, olmesartan medoxomil/hydrochlorothiazide tablets
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female Europeans aged 18 years or older with moderate to severe hypertension
             (HTN)

        Exclusion Criteria:

          -  Female patients of childbearing potential pregnant, lactating or planning to become
             pregnant during the trial period.

          -  Patients with serious disorders which may limit the ability to evaluate the efficacy
             or safety of the study medication, including cerebrovascular, cardiovascular, renal,
             respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or
             oncological, neurological and psychiatric diseases.

          -  Patients having a history of the following within the last six months:

               -  myocardial infarction,

               -  unstable angina pectoris,

               -  percutaneous coronary intervention,

               -  severe heart failure,

               -  hypertensive encephalopathy,

               -  cerebrovascular accident (stroke) or

               -  transient ischaemic attack.

          -  Patients with clinically significant abnormal laboratory values at screening.

          -  Patients with secondary HTN.
Clinical trial NCT01574651 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: qva149, placebo to tiotropium, placebo to formoterol, tiotropium, formoterol, placebo to qva149
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥ 40 yrs

          -  Patients with moderate to severe chronic obstructive pulmonary disease (GOLD 2010
             guidelines)

          -  Smoking history of at least 10 pack years

          -  Post-bronchodilator FEV1 < 80% and ≥30% of the predicted normal value and
             post-bronchodilator FEV1/FVC (forced vital capacity) <70%

        Exclusion Criteria:

          -  Pregnant women or nursing mothers or women of child-bearing potential not using
             adequate contraception

          -  Patients with a history of long QT syndrome

          -  Patients with Type I or uncontrolled Type II diabetes

          -  Patients who have had a COPD exacerbation or respiratory tract infection within 6
             weeks prior to screening

          -  Patients with any history of asthma

          -  Patients with pulmonary lobectomy, lung volume reduction surgery, or lung
             transplantation

          -  Patients with concomitant pulmonary disease

          -  Patients requiring long term oxygen therapy (>15 h a day)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00691964 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Psoriasis for 6 mo.

          -  BSA 10%, PASI 12 or above, PGA 3 or above

        Exclusion Criteria:

          -  Previous exposure to either etanercept or ABT-874
Clinical trial NCT01269463 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder, adhd
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: methylphenidate hydrochloride extended release capsules, placebo
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males and females ages 6 to 12.

          2. ADHD diagnosis with ADHD-RS-IV scores ≥ 90th percentile.

          3. In need of treatment for ADHD and able to have 2-day washout from previous medication.

          4. Females of child-bearing potential not pregnant and practice birth control.

          5. Subject and parent/guardian willing to comply with protocol.

          6. Signed consent and assent.

        Exclusion Criteria:

          1. IQ less than 80 WASI.

          2. Current primary psychiatric diagnosis of: severe anxiety disorder, conduct disorder,
             psychotic disorders, pervasive developmental disorder, eating disorder,
             obsessive-compulsive disorder, major depressive disorder, bipolar disorder, substance
             use disorder, chronic tic disorder, personal or family history of Tourette's Syndrome.

          3. Chronic medical illnesses: seizure, hypertension, thyroid disease, cardiac, family
             history of sudden death, glaucoma.

          4. Use of psychotropic CNS meds having effect exceeding 14 days from screening.

          5. Planned use of prohibited drugs.

          6. Is pregnant or breast-feeding.

          7. Significant ECG or laboratory abnormalities.

          8. Experimental drug or medical device within 30 days prior to screening.

          9. Hypersensitivity to methylphenidate.

         10. Inability or unwillingness to comply with protocol.

         11. Well controlled on current ADHD treatment.

         12. Inability to take oral capsules.
Clinical trial NCT00623636 (phase 3, status: completed)
Conditions: migraine disorders
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: map0004, placebo
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Major Inclusion Criteria:

          -  Male or female between 18 and 65 years of age.

          -  History of episodic, acute migraine (with or without aura) with onset prior to 50

        Major Exclusion Criteria:

          -  Known allergy or sensitivity or contraindication to study drugs or their formulations

          -  History of chronic pulmonary disease, coronary artery disease (CAD), liver disease,
             kidney disease, seizures, stroke, or major psychiatric condition.

          -  Any condition that, in the opinion of the Investigator, would make the subject
             unsuitable for study participation
Clinical trial NCT01709864 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: nva237, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with
             airflow obstruction of level 2 and 3 according to the current Global initiative for
             chronic Obstructive Lung Disease (GOLD) strategy (2011).

          2. Patients with Forced Expiratory Volume in one second (FEV1) ≥ 30% and <80 % of the
             predicted normal, and FEV1/ Forced Vital Capacity (FVC) < 0.70 when measured 45 min
             after the inhalation of 84 µg ipratropium bromide.

          3. Current or ex-smokers with at least 10 cigarette pack years smoking history.

        Exclusion criteria:

          1. Patients with a history of long QT syndrome, with a prolonged QTc measured during
             screening, or patients who have a clinically significant ECG abnormality at screening.

          2. History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years, regardless of whether
             there is evidence of local recurrence or metastases.

          3. Pregnant or nursing (lactating) women. Women of childbearing potential unless using an
             effective method of contraception.

          4. Patients who in the judgment of the investigator, would be at potential risk if
             enrolled into the study.

          5. Patients who have a clinically significant concomitant disease at screening, including
             but not limited to clinically significant laboratory abnormalities, clinically
             significant renal, cardiovascular, neurological, endocrine, immunological,
             psychiatric, gastrointestinal, hepatic, or hematological abnormalities, or with
             uncontrolled diabetes, which could interfere with the assessment of the efficacy and
             safety of the study treatment.

          6. Patients with a body mass index (BMI) of more than 40 kg/m2.

          7. Patients contraindicated for treatment with, or having a history of reactions/
             hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, or
             sympathomimetic amines.

          8. Patients with any history of asthma, with onset of symptoms prior to age 40 years, or
             patients with a high blood eosinophil count during screening.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00340834 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: fingolimod 1.25 mg, fingolimod 0.5 mg, interferon β-1a 30 µg
SMILES: CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1, CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis
             (MS)

          -  Patients with a relapsing-remitting disease course

          -  Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5

        Exclusion Criteria:

          -  Patients with other chronic disease of the immune system, malignancies, acute
             pulmonary disease, cardiac failure, etc

          -  Pregnant or nursing women

          -  Patients who cannot tolerate treatment with an interferon

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT01045707 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  For MAIN period (NN5401-3590):

          -  Diagnosis of type 2 diabetes mellitus for at least 6 months

          -  Insulin naïve subjects

          -  Treatment with metformin and at least one other oral antidiabetic drug for at least 3
             months before trial start

          -  Glycosylated haemoglobin (HbA1c) between 7.5 - 11.0% (both inclusive)

          -  Body Mass Index (BMI) no higher than 40.0 kg/m^2

          -  For EXTENSION period (NN5401-3726):

          -  Informed consent obtained before any trial-related activities

          -  Must have completed the 26-week treatment period (visit 28) in trial NN5401-3590

        Exclusion Criteria:

          -  For MAIN period (NN5401-3590):

          -  Treatment with glucagon like peptide-1 (GLP-1) receptor agonists and/or
             thiazolidinedione(s) within the last 3 months prior to trial start

          -  Cardiovascular disease diagnosed within 6 months before trial start

          -  For EXTENSION period (NN5401-3726):

          -  Anticipated change in concomitant medication known to interfere significantly with
             glucose metabolism, such as systemic corticosteroids, beta-blockers, Monoamine oxidase
             (MAO) inhibitors

          -  Anticipated significant lifestyle changes during the trial, e.g. shift work (including
             permanent night/evening shift workers), as well as highly variable eating habits as
             judged by the physician)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements